Abstract: Recently, with the development of new drugs, treatment of light chain amyloidosis has been enriched. As an important therapeutic target, antiCD38 monoclonal antibodies has been developed for plasma cell diseases and has been successful in multiple myeloma. Since then, antiCD38 monoclonal antibodies have been used for the treatment of light chain amyloidosis, and series of research results have been published, showing encouraging efficacy and safety. This article will review research progress of antiCD38 monoclonal antibodies in treatment of light chain amyloidosis.

Key words: anti-CD38 monoclonal antibody, light chain amyloidosis, efficacy, adverse events